TY - JOUR
T1 - Phase II study of iproplatin (CHIP, JM-9) in advanced testicular cancers progressing after prior chemotherapy
AU - Clavel, Michel
AU - Monfardini, Silvio
AU - Gundersen, Stein
AU - Kaye, Stanley
AU - Siegenthaler, Pierre
AU - Renard, Josette
AU - Van Glabbeke, Martine
AU - Pinedo, Herbert M.
PY - 1988
Y1 - 1988
N2 - Twenty-two patients with advanced testicular cancer received iproplatin at a dose of 180-240 mg/m2 every 4 weeks. All the patients progressed or recurred after chemotherapy including cisplatin. The most severe toxicity was thrombocytopenia with two toxic deaths after a first cycle of 240 and 180 mg/m2 respectively. Nausea and vomiting were almost universal but mild in intensity. One renal failure occurred 6 weeks after the first cycle while the tumor was progressing. No antitumor activity was observed in this heavily pretreated population of patients.
AB - Twenty-two patients with advanced testicular cancer received iproplatin at a dose of 180-240 mg/m2 every 4 weeks. All the patients progressed or recurred after chemotherapy including cisplatin. The most severe toxicity was thrombocytopenia with two toxic deaths after a first cycle of 240 and 180 mg/m2 respectively. Nausea and vomiting were almost universal but mild in intensity. One renal failure occurred 6 weeks after the first cycle while the tumor was progressing. No antitumor activity was observed in this heavily pretreated population of patients.
UR - http://www.scopus.com/inward/record.url?scp=0023732563&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023732563&partnerID=8YFLogxK
U2 - 10.1016/0277-5379(88)90226-X
DO - 10.1016/0277-5379(88)90226-X
M3 - Article
C2 - 3181255
AN - SCOPUS:0023732563
SN - 0277-5379
VL - 24
SP - 1345
EP - 1348
JO - European Journal of Cancer and Clinical Oncology
JF - European Journal of Cancer and Clinical Oncology
IS - 8
ER -